Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance

Leukemia volume 28, pages 174–178 (2014)Cite this article

Subjects

Abstract

Radiological skeletal survey or computed tomography are currently applied to assess bone diseases in patients with monoclonal plasma cell disorders. Whole-body magnetic resonance imaging (whole-body MRI) allows detecting the infiltration of clonal cells in nearly the whole bone marrow compartment even before bone destruction has occurred. Those MRI results (i.e., patterns of bone marrow infiltration) have been demonstrated to be of prognostic significance in patients with symptomatic as well as asymptomatic multiple myeloma. We have therefore analyzed the findings of whole-body MRI in 137 consecutive individuals with monoclonal gammopathy of undetermined significance (MGUS). A focal infiltration pattern was detected in 23.4% of patients. Presence and number of focal lesions as well as value of M-Protein were of independent prognostic significance for progression into a symptomatic disease requiring systemic treatment (P=0.02; P<0.0001 and P=0.0005, respectively). Lower homogeneous signal intensities in T1-weighted images were related to a physiologically higher bone marrow cellularity in younger individuals (P=0.002). We conclude that whole-body MRI identifies patients with focal accumulations of presumably monoclonal cells in bone marrow with prognostic impact concerning the risk of progression into symptomatic disease.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Axelsson U, Bachmann R, Hällén J . Frequency of pathological proteins (M-components) from 6,995 sera from an adult population. Acta Med Scand 1966; 179: 235–247.

    Article  CAS  Google Scholar 

  2. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med 2002; 346: 564–569.

    Article  Google Scholar 

  3. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749–757.

    Article  Google Scholar 

  4. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 2009; 113: 5412–5417.

    Article  CAS  Google Scholar 

  5. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010; 24: 1121–1127.

    Article  CAS  Google Scholar 

  6. Rajkumar SV, Kyle RA, Therneau TM, Melton LJ 3rd, Bradwell AR, Clark RJ et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 2005; 106: 812–817.

    Article  CAS  Google Scholar 

  7. Pérez-Persona E, Mateo G, García-Sanz R, Mateos MV, de Las Heras N, de Coca AG et al. Risk of progression in smouldering myeloma and monoclonal gammopathies of unknown significance: comparative analysis of the evolution of monoclonal component and multiparameter flow cytometry of bone marrow plasma cells. Br J Haematol 2010; 148: 110–114.

    Article  Google Scholar 

  8. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica 2007; 92: 50–55.

    Article  Google Scholar 

  9. Gleeson TG, Moriarty J, Shortt CP, Gleeson JP, Fitzpatrick P, Byrne B et al. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI). Skeletal Radiol 2009; 38: 225–236.

    Article  CAS  Google Scholar 

  10. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011; 117: 4701–4705.

    Article  CAS  Google Scholar 

  11. Hillengass J, Fechtner K, Weber MA, Bäuerle T, Ayyaz S, Heiss C et al. Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 2010; 28: 1606–1610.

    Article  Google Scholar 

  12. Moulopoulos LA, Dimopoulos MA, Christoulas D, Kastritis E, Anagnostou D, Koureas A et al. Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents. Leukemia 2010; 24: 1206–1212.

    Article  CAS  Google Scholar 

  13. Walker R, Barlogie B, Haessler J, Tricot G, Anaissie E, Shaughnessy JD Jr et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications. J Clin Oncol 2007; 25: 1121–1128.

    Article  Google Scholar 

  14. Fechtner K, Hillengass J, Delorme S, Heiss C, Neben K, Goldschmidt H et al. Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems. Radiology 2010; 257: 195–204.

    Article  Google Scholar 

  15. Baur A, Stäbler A, Nagel D, Lamerz R, Bartl R, Hiller E et al. Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon? Cancer 2002; 95: 1334–1345.

    Article  Google Scholar 

  16. Stäbler A, Baur A, Bartl R, Munker R, Lamerz R, Reiser MF . Contrast enhancement and quantitative signal analysis in MR imaging of multiple myeloma: assessment of focal and diffuse growth patterns in marrow correlated with biopsies and survival rates. AJR Am J Roentgenol 1996; 167: 1029–1036.

    Article  Google Scholar 

  17. Gray RJ . A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann of Statistics 1988; 16: 1141–1154.

    Article  Google Scholar 

  18. Fine JP, Gray RJ . A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94: 496–509.

    Article  Google Scholar 

  19. Lausen B, Hothorn T, Bretz F, Schumacher M . Assessment of optimal selected prognostic factors. Biom J 2004; 46: 364–374.

    Article  Google Scholar 

  20. R Development Core Team 2012 R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, ISBN 3-900051-07-0, URL: http://www.R-project.org/.

  21. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Melton LJ 3rd, Colby CL et al. Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study. Lancet 2010; 375: 1721–1728.

    Article  Google Scholar 

  22. Baur-Melnyk A, Buhmann S, Becker C, Schoenberg SO, Lang N, Bartl R et al. Whole-body MRI versus whole-body MDCT for staging of multiple myeloma. AJR Am J Roentgenol 2008; 190: 1097–1104.

    Article  Google Scholar 

  23. Vande Berg BC, Michaux L, Lecouvet FE, Labaisse M, Malghem J, Jamart J et al. Nonmyelomatous monoclonal gammopathy: correlation of bone marrow MR images with laboratory findings and spontaneous clinical outcome. Radiology 1997; 202: 247–251.

    Article  CAS  Google Scholar 

  24. Bäuerle T, Hillengass J, Fechtner K, Zechmann CM, Grenacher L, Moehler TM et al. Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging. Radiology 2009; 252: 477–485.

    Article  Google Scholar 

  25. Waheed S, Mitchell A, Usmani S, Epstein J, Yaccoby S, Nair B et al. Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data. Haematologica 2013; 98: 71–78.

    Article  CAS  Google Scholar 

  26. Baur A, Stäbler A, Bartl R, Lamerz R, Reiser M . Infiltration patterns of plasmacytomas in magnetic resonance tomography. Rofo 1996; 164: 457–463.

    Article  CAS  Google Scholar 

  27. Moulopoulos LA, Gika D, Anagnostopoulos A, Delasalle K, Weber D, Alexanian R et al. Prognostic significance of magnetic resonance imaging of bone marrow in previously untreated patients with multiple myeloma. Ann Oncol 2005; 16: 1824–1828.

    Article  CAS  Google Scholar 

  28. Lecouvet FE, Vande Berg BC, Michaux L, Malghem J, Maldague BE, Jamart J et al. Stage III multiple myeloma: clinical and prognostic value of spinal bone marrow MR imaging. Radiology 1998; 209: 653–660.

    Article  CAS  Google Scholar 

  29. Fonti R, Salvatore B, Quarantelli M, Sirignano C, Segreto S, Petruzziello F et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med 2008; 49: 195–200.

    Article  Google Scholar 

  30. Moulopoulos LA, Dimopoulos MA, Kastritis E, Christoulas D, Gkotzamanidou M, Roussou M et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients. Am J Hematol 2012; 87: 861–864.

    Article  Google Scholar 

  31. Baur A, Stäbler A, Bartl R, Lamerz R, Scheidler J, Reiser M . MRI gadolinium enhancement of bone marrow: age-related changes in normals and in diffuse neoplastic infiltration. Skeletal Radiol 1997; 26: 414–418.

    Article  CAS  Google Scholar 

  32. Hillengass J, Stieltjes B, Bäuerle T, McClanahan F, Heiss C, Hielscher T et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals. Acta Radiol 2011; 52: 324–330.

    Article  Google Scholar 

  33. Hillengass J, Ayyaz S, Kilk K, Weber MA, Hielscher T, Shah R et al. Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma. Haematologica 2012; 97: 1757–1760.

    Article  Google Scholar 

Download references

Acknowledgements

Parts of this study were supported by grants from the International Myeloma Foundation, the Dietmar Hopp Stiftung and the German Research Foundation (SFB Transregio 79).

Author information

Authors and Affiliations

  1. Department of Hematology and Oncology, University of Heidelberg, Heidelberg, Germany

    J Hillengass, B Wagner-Gund, M Hillengass, A Farid, K Neben & H Goldschmidt

  2. Department of Radiology, German Cancer Research Center, Heidelberg, Germany

    J Hillengass & S Delorme

  3. Department of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, Germany

    M-A Weber, K Kilk & K Listl

  4. Department of Biostatistics, German Cancer Research Center, Heidelberg, Germany

    T Hielscher

  5. Metabolism Branch, National Cancer Institute, Bethesda, MD, USA

    O Landgren

  6. National Center for Tumor Diseases, Heidelberg, Germany

    H Goldschmidt

Authors
  1. J Hillengass
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M-A Weber
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K Kilk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. K Listl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Wagner-Gund
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Hillengass
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Hielscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Farid
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Neben
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. S Delorme
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. O Landgren
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. H Goldschmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J Hillengass.

Ethics declarations

Competing interests

The authors declare no conflict of Interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hillengass, J., Weber, MA., Kilk, K. et al. Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia 28, 174–178 (2014). https://doi.org/10.1038/leu.2013.244

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2013.244

Keywords

This article is cited by

Search

Advanced search

Quick links